A Phase 2 Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer’s Disease. The study medication is an OGA Inhibitor which slows the accumulation of hyperphosphorylated tau (oral), a key driver of worsening Alzheimer’s tangle pathology.

Eligibility includes:
Age 60-85
Participants must have gradual and progressive changes in memory for at least 6 months
Have a study partner who will provide written informed consent to participate


    Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Contact Us For More Info